Compare · BTMD vs DFTX
BTMD vs DFTX
Side-by-side comparison of Biote Corp. (BTMD) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BTMD and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $2.70B, about 29.2x BTMD ($92.5M).
- Over the past year, BTMD is down 37.8% and DFTX is up 245.6% - DFTX leads by 283.4 points.
- BTMD has been more active in the news (5 items in the past 4 weeks vs 2 for DFTX).
- Both have 4 recent analyst ratings on file.
PerformanceBTMD-37.82%DFTX+245.60%
2025-06-16+0.00%2026-06-12
- Company
- Biote Corp.
- Definium Therapeutics Inc.
- Price
- $2.45+0.82%
- $24.75+2.66%
- Market cap
- $92.5M
- $2.70B
- 1M return
- +20.39%
- +12.38%
- 1Y return
- -37.82%
- +245.60%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 5
- 2
- Recent ratings
- 4
- 4
Latest BTMD
- SEC Form 4 filed by Director Christensen Bret
- SEC Form 4 filed by Executive Chairman Beer Marc D
- Biote Corp. filed SEC Form 8-K: Leadership Update
- Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer
- Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO
- SEC Form 8-K filed by Biote Corp.
- SEC Form 4 filed by Director Heyer Andrew R
- Director Morris Debra L converted options into 21,407 shares, increasing direct ownership by 43% to 71,562 units (SEC Form 4)
- SEC Form 4 filed by Director Cone Stephen Mark
- SEC Form 4 filed by Director Jacoby Dana Lynn
Latest DFTX
- Definium Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 10-Q filed by Definium Therapeutics Inc.
- Definium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights